Drug Profile
Research programme: inositol hexaphosphate analogue - Inositec
Alternative Names: IP6 - Inositec; OEG4-(IP5)2Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Inositec
- Class Antibacterials; Antitoxins; Calcium regulators; Inositol phosphates; Small molecules; Sugar alcohols
- Mechanism of Action Bacterial toxin inhibitors; Metabolism inhibitors; Oxalate inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Clostridium difficile infections
Highest Development Phases
- No development reported Clostridium difficile infections; Kidney disorders; Vascular calcification
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Kidney-disorders in Switzerland (SC)
- 02 Aug 2022 Vifor Pharma has been acquired by CSL and renamed to CSL Vifor
- 28 Nov 2020 No recent reports of development identified for preclinical development in Clostridium-difficile-infections in Switzerland (PO)